T. Mansy

659 total citations
11 papers, 199 citations indexed

About

T. Mansy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, T. Mansy has authored 11 papers receiving a total of 199 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 2 papers in Surgery. Recurrent topics in T. Mansy's work include Lung Cancer Diagnosis and Treatment (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (4 papers). T. Mansy is often cited by papers focused on Lung Cancer Diagnosis and Treatment (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (4 papers). T. Mansy collaborates with scholars based in United Kingdom, United States and Germany. T. Mansy's co-authors include Corinne Faivre‐Finn, Srinivasan Madhusudan, Abed Zaitoun, Shalini Malhotra, Rajeev Singh, Gavin Young, Maria Rita Migliorino, Marina Chiara Garassino, Laura Cove-Smith and Niels Reinmuth and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Muscle & Nerve.

In The Last Decade

T. Mansy

10 papers receiving 194 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Mansy United Kingdom 6 162 108 40 22 11 11 199
Mikako Ishijima Japan 7 107 0.7× 122 1.1× 27 0.7× 16 0.7× 5 0.5× 15 176
Patrizia Guerrieri United States 5 97 0.6× 117 1.1× 46 1.1× 26 1.2× 5 0.5× 12 170
Nikhil Pande India 10 132 0.8× 134 1.2× 54 1.4× 13 0.6× 8 0.7× 30 227
Ina Valeria Zurlo Italy 6 89 0.5× 105 1.0× 42 1.1× 15 0.7× 6 0.5× 24 191
N. Girard France 4 73 0.5× 81 0.8× 13 0.3× 11 0.5× 6 0.5× 24 110
Yujia Chi China 11 125 0.8× 110 1.0× 13 0.3× 20 0.9× 4 0.4× 20 209
Margaux Geier France 8 150 0.9× 167 1.5× 12 0.3× 18 0.8× 3 0.3× 41 220
Jennifer Arena Australia 8 59 0.4× 173 1.6× 61 1.5× 14 0.6× 21 1.9× 15 194
Aurelia Alexandru Romania 8 111 0.7× 111 1.0× 10 0.3× 7 0.3× 4 0.4× 24 155
Mojca Unk Slovenia 6 117 0.7× 134 1.2× 15 0.4× 69 3.1× 3 0.3× 14 193

Countries citing papers authored by T. Mansy

Since Specialization
Citations

This map shows the geographic impact of T. Mansy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Mansy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Mansy more than expected).

Fields of papers citing papers by T. Mansy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Mansy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Mansy. The network helps show where T. Mansy may publish in the future.

Co-authorship network of co-authors of T. Mansy

This figure shows the co-authorship network connecting the top 25 collaborators of T. Mansy. A scholar is included among the top collaborators of T. Mansy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Mansy. T. Mansy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Garassino, Marina Chiara, Jonathan Khalifa, Martin Reck, et al.. (2025). Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial. ESMO Open. 10(6). 105071–105071. 2 indexed citations
2.
Garassino, M.C., Julien Mazières, Martin Reck, et al.. (2023). LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6. Annals of Oncology. 34. S1301–S1302. 3 indexed citations
3.
Garassino, Marina Chiara, Julien Mazières, Martin Reck, et al.. (2022). Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. Journal of Thoracic Oncology. 17(12). 1415–1427. 69 indexed citations
4.
Garassino, M.C., Martin Reck, C. Chouaïd, et al.. (2022). 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6). Annals of Oncology. 33. S81–S82. 11 indexed citations
6.
Lester, J., Carles Escriu, Sabbir Khan, et al.. (2020). 1379P Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom. Annals of Oncology. 31. S878–S879. 2 indexed citations
7.
Bayman, N., W. Appel, Linda Ashcroft, et al.. (2019). Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. Journal of Clinical Oncology. 37(14). 1200–1208. 36 indexed citations
8.
Young, Gavin, et al.. (2018). Guillain–Barré‐like syndrome during pembrolizumab treatment. Muscle & Nerve. 58(1). 19 indexed citations
9.
Bayman, N., W. Appel, Linda Ashcroft, et al.. (2018). Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: results of a multicentre phase III trial. Lung Cancer. 115. S30–S30.
10.
Bayman, N., W. Appel, Linda Ashcroft, et al.. (2017). OA 02.03 Prophylactic Irradiation of Tracts (PIT) in Patients with Pleural Mesothelioma: Results of a Multicenter Phase III Trial. Journal of Thoracic Oncology. 12(11). S1747–S1747. 4 indexed citations
11.
Malhotra, Shalini, et al.. (2010). Intrahepatic Sarcomatoid Cholangiocarcinoma. Journal of Oncology. 2010. 1–4. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026